Regenerative Medicine's Next Chapter: Inside the Race to Make the Body Rebuild Itself
Globe Newswire (Thu, 18-Jun 12:42 PM ET)
Craig-Hallum Sticks to Their Buy Rating for MiMedx Group (MDXG)
TipRanks (Thu, 18-Jun 5:46 AM ET)
The Quiet Revolution in Regenerative Medicine: From Replacing Tissue to Rebuilding It
Globe Newswire (Tue, 16-Jun 10:30 AM ET)
A Fresh FDA Catalyst Is Putting Regenerative Wound Care in Focus
Globe Newswire (Tue, 9-Jun 9:55 AM ET)
MIMEDX to Participate in Craig-Hallum 23rd Annual Institutional Investor Conference
Globe Newswire (Thu, 21-May 8:45 AM ET)
Globe Newswire (Tue, 19-May 6:15 PM ET)
MIMEDX Announces Launch of G4Derm Plus
Globe Newswire (Fri, 8-May 8:00 AM ET)
Globe Newswire (Thu, 30-Apr 4:43 PM ET)
MDXG Lowers Sales Outlook After Wound Care Disruption, but Surgical Growth Remains a Bright Spot
Market Chameleon (Thu, 30-Apr 7:13 AM ET)
MIMEDX Announces First Quarter 2026 Operating & Financial Results
Globe Newswire (Wed, 29-Apr 4:01 PM ET)
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
Mimedx Group trades on the NASDAQ stock market under the symbol MDXG.
As of June 23, 2026, MDXG stock price climbed to $3.73 with 806,114 million shares trading.
MDXG has a beta of 0.71, meaning it tends to be less sensitive to market movements. MDXG has a correlation of 0.06 to the broad based SPY ETF.
MDXG has a market cap of $555.57 million. This is considered a Small Cap stock.
Last quarter Mimedx Group reported $59 million in Revenue and -$.05 earnings per share. This fell short of revenue expectation by $-5 million and missed earnings estimates by -$.01.
In the last 3 years, MDXG traded as high as $10.14 and as low as $3.03.
The top ETF exchange traded funds that MDXG belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.
MDXG has underperformed the market in the last year with a return of -35.8%, while the SPY ETF gained +24.7%. In the last 3 month period, MDXG fell short of the market, returning -9.5%, while SPY returned +13.4%. However, in the most recent 2 weeks MDXG has outperformed the stock market by returning +0.8%, while SPY returned -0.5%.
MDXG support price is $3.59 and resistance is $3.75 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MDXG shares will trade within this expected range on the day.
